PRDM1 expression positively correlates with the expression of LAG3, CTLA4, PDCD1 (PD-1), CD274 (PD-L1), PDCD1LG2 (PD-L2), TIGIT in the majority of 33 cancer types, and GSEA demonstrated the high PRDM1 patient group negatively enriched terms including B cell receptor signaling, T cell receptor signaling and cytokine cytokine receptor interaction, IL-2-STAT5 signaling and allograft rejection. This evidence concerns the gene PDCD1LG2 and cancer.